Výsledky vyhledávání - "Anita Sultan"

Akademický článek

Wellens’ sign: A reliable ECG sign for proximal left anterior descending coronary artery disease

Autor: Ragesh Panikkath, Deepa Panikkath, Anita Sultan, Leigh Ann Jenkins

Publikováno v: Southwest Respiratory and Critical Care Chronicles, Vol 3, Iss 9, Pp 33-34 (2014)

Externí odkaz: https://doaj.org/article/7cee4489977f499484b2365ad8e8fad6

CLO19-059: A Systematic Review and Meta- Analysis of Randomized Controlled Trials to Evaluate the Risk of Health-Related Quality of Life Events in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated With CDK 4/6 Inhibitors

Autor: Miguel Quirch, Yin Mon Myat, Catherine Jones, Anita Sultan, Somedeb Ball, Sriman Swarup, Kyaw Zin Thein, Rachana Yendala, Myo H. Zaw

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-059

Background: Pain, fatigue, hot flushes, and rash significantly contribute to quality of life in breast cancer patients undergoing chemotherapy. Hormone receptor-positive breast cancer is a common entity among women worldwide. In cancer cells, CDK4/6

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe12a5390656c962f72b12283cece7e7
https://doi.org/10.6004/jnccn.2018.7234

Zobrazit plný text záznamu

EPR19-071: Risk of Hematologic Toxicities and Health-Related Quality of Life Events in Patients With Hematologic Malignancies Treated With Ibrutinib: A Combined Analysis of 6 Phase III Trials

Autor: Zayar M. Oo, Miguel Quirch, Nyein H. Yu, Donald P. Quick, Sriman Swarup, Kyaw Zin Thein, Anita Sultan, Wai Lin Thein, Myo H. Zaw

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:EPR19-071

Background: Bruton’s tyrosine kinase (BTK) is essential for signaling of B-cell and chemokine receptors. Ibrutinib targets BTK and has become frontier in many hematologic malignancies. We undertook systematic review and pooled analysis of randomize

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc921d36fd892699fb9b96507d7c3e8e
https://doi.org/10.6004/jnccn.2018.7151

Zobrazit plný text záznamu

CLO19-052: Incidence of Ribociclib-Associated Cardiac Conduction Abnormalities in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer: A Combined Analysis of 3 Phase III Randomized Controlled Trials

Autor: Somedeb Ball, Myo H. Zaw, Anita Sultan, Catherine Jones, Sriman Swarup, Fred Hardwicke, Kyaw Zin Thein, Sanjay Awasthi, Lukman Tijani

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-052

Introduction: Ribociclib, a cyclin-dependent kinase 4/6 inhibitor, has improved survival in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER 2)-negative advanced breast cancer. Despite remarkable efficacy, p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f081d82ab489a3027a79a92dcbee4807
https://doi.org/10.6004/jnccn.2018.7154

Zobrazit plný text záznamu

CLO19-050: Risk of Health- Related Quality of Life (HRQOL) Events in Patients With Advanced Solid Tumors Treated With Cabozantinib: A Combined Analysis of Four Phase 3 Randomized Controlled Trials

Autor: Sriman Swarup, Nimesh Adhikari, Anita Sultan, Myo Zaw, Ye Aung, Kyaw Zin Thein, Yin Mon Myat, Nusrat Jahan, Upama Sharma

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-050

Background: VEGFR, KIT, RET, and MET pathways are implicated in several solid tumors. Cabozantinib is an oral inhibitor of these kinase pathways, and hence has found its use in treatment of multiple malignancies. However, it has several side effects

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47360a58d2ea8083b38fd60961221fef
https://doi.org/10.6004/jnccn.2018.7150

Zobrazit plný text záznamu

EPR19-73: Risk of Gastrointestinal and Hepatic Toxicities in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors

Autor: Kyaw Zin Thein, Anita Sultan, Ye Aung, Sriman Swarup, Meily Arevalo, Miguel Quirch, Somedeb Ball, Myo H. Zaw, Yin Mon Myat

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:EPR19-73

Background: CDK4 and CDK6 are cyclin-dependent kinases that control transition between G1 and S phases of the cell cycle, hence controlling cell cycle progression by reversible combination with cyclin D1. In cancer cell, CDK4/6 activity is overexpres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4999556a7441ebd1858b9322e1f4bc9a
https://doi.org/10.6004/jnccn.2018.7153

Zobrazit plný text záznamu

CLO19-051: CDK 4/6 Inhibitor-Associated Hematologic Toxicities and Febrile Neutropenia in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

Autor: Yin Mon Myat, Somedeb Ball, Nimesh Adhikari, Catherine Jones, Anita Sultan, Sriman Swarup, Kyaw Zin Thein, Myo H. Zaw, Francis Mogollon-Duffo

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-051

Background: Breast cancer is the most common cancer in women, and the majority of breast cancers express the estrogen receptor or progesterone receptor. Inhibition of CDK4/6 signaling pathway has shown survival benefit in advanced breast cancer by ov

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4b0b4bbc0fbf3cefb2dea7c939c61ca
https://doi.org/10.6004/jnccn.2018.7152

Zobrazit plný text záznamu

CLO19-024: Risk of Atrial Fibrillation and Pulmonary Toxicities in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated With Ibrutinib

Autor: Khaing Khaing Htwe, Anita Sultan, Tun W. Naing, Upama Sharma, Kyaw Zin Thein, Myo H. Zaw, Wai P. Thi, Sriman Swarup, Nimesh Adhikari, Nay N. Yee

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-024

Background: Bruton’s tyrosine kinase (BTK), a kinase downstream of the B-cell receptor, involves in the B cell survival and proliferation and has become an attractive therapeutic target. Ibrutinib is an oral potent, covalent inhibitor of BTK and he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a87cb3ee2c2da6df6d1ad9a7b2175b8a
https://doi.org/10.6004/jnccn.2018.7158

Zobrazit plný text záznamu

CLO19-025: Treatment Discontinuation Due to Adverse Events and the Risk of Gastrointestinal Toxicities in Patients With Hematologic Malignancies Treated With Ibrutinib

Autor: Sriman Swarup, Nay N. Yee, Kyaw Zin Thein, Myo H. Zaw, Wai Lin Thein, Meily Arevalo, Anita Sultan, Nusrat Jahan, Myet Mon Mon Zin

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-025

Background: Ibrutinib targets Bruton’s tyrosine kinase, a kinase involved in signaling of B-cell and chemokine receptors, which are implicated in the pathogenesis of hematologic malignancies. Ibrutinib has been shown to improve survival in hematolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b71d8e4265f6eee60ef3fb74a06d8ae5
https://doi.org/10.6004/jnccn.2018.7171

Zobrazit plný text záznamu

EPR19-74: Risk of Cabozantinib-Associated Gastrointestinal and Hepatic Toxicities in Patients With Metastatic Solid Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Autor: Myo H. Zaw, Anita Sultan, Ye Aung, Sriman Swarup, Kyaw Zin Thein, Rachana Yendala, Nicholas D'Cunha, Francis Mogollon-Duffo, Yin Mon Myat

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:EPR19-74

Background: Cabozantinib is an oral inhibitor of multiple tyrosine kinases and is used in treatment of multiple solid tumors, targeting several pathways such as vascular endothelial growth factor signaling pathway and proto-oncogenes MET, KIT, RET. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::332243a922627cc3d770dde473a497b1
https://doi.org/10.6004/jnccn.2018.7155

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání